AzurBio Pharma, specializing in bringing innovative pharmaceutical products to European markets and focusing on rare and serious diseases with unmet medical needs, is announcing its official launch. AzurBio Pharma is headquartered in Paris with a presence in both Europe and the US.

AzurBio Pharma offers biopharmaceutical companies strategic partnerships and flexible solutions to enter the EU market, from registration to commercialization, streamlining the complex market entry process in Europe, and reducing time-to-market and operational challenges.

AzurBio Pharma's initial offerings include a disruptive turnkey solution to accelerate time-to-market in France, a country in Europe that offers a unique structured pathway for early access to medicines addressing unmet medical needs, with potential for reimbursement through its healthcare system.

"As CEO and founder of AzurBio Pharma, I am thrilled to introduce our mission to unlock entry to the European markets for groundbreaking treatments by expertly navigating the regulatory landscape and fast-tracking access to key markets when and where possible" said CEO Corinne Schmitz, who also founded BlueReg and PharmaBlue. " Our team’s deep European expertise enables us to tailor solutions that address the specific needs of North American companies seeking faster, smoother entry into Europe.”

Guided by an elite strategic committee, AzurBio Pharma is well-positioned to deliver on its mission. Non-executive members of the committee include industry leaders like Antoine Barouky, Former VP General Manager & International Business Development at Alnylam, Marc Lefrançois, Health Industry Partner at CMI, and Stephane Andre, Former SVP of Global Regulatory Affairs at Ipsen, each bringing decades of expertise in biopharma leadership, European market entry strategy, and global regulatory affairs.